Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Hypoactive sexual desire disorder (HSDD) is the most common sexual complaint in women. Over the past 8 years, Dr. Stephanie Cacioppo has developed and validated the Desire Intention task, in which individuals are instructed to indicate as rapidly and as accurately as possible whether or not each visually presented stimulus (e.g., attractive persons of the opposite sex) is sexually desirable to them at the moment of the experiment. Flibanserin (Addyi) is a new medication approved by the FDA for the treatment of HSDD in pre-menopausal women. The investigators propose a study using the DIT to determine the extent to which Flibanserin normalizes brain activity in women with HSDD and the extent to which regional brain activation is associated with changes in symptoms and behavior.
Age
21–74
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female
Ages 21-45 or 51-74
Pre- or Postmenopausal
DSM-5 diagnosis of hypoactive sexual desire disorder (HSDD)
Right-handed
You may not be if
Male
Pregnant women
Nursing women
Post-menopausal women
Women who report not being able to stop drinking alcohol during the duration of the study
Currently taking psychotropic medication
History of seizures or neurological disorders
Under hormonal therapy
Current or past diagnosis of cancer
Any unstable medical illnesses
Lifetime history of bipolar disorder, schizophrenia, or psychotic disorder
Current or recent (past 3 months) substance abuse or dependence
Current or recent (past 3 months) clinical depression
Currently taking any medications that have/may have unfavorable interactions with Flibanserin